Catalysts AbbVie Investors Need To Watch

In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for AbbVie Inc ABBV. These include:

• Quarterly calls - Viekira Pak sales in Hep C
• Mid-April 2015 - Phase 2b 12-week RA data JAK1 GLPG0634
• 1H15 - ABT-199 Phase 2 data for del 17p R/R CLL
• 1H15 - ABT-494 Phase 2b data in RA
• 1H15 - Elotuzumab ph3 data in myeloma
• Mid-year 2015 (ISI estimate) - Elagolix 12 month data from phase 3 in endometriosis
• 2H15 - Elagolix Phase 2b data for Uterine Fibroids
• 2H15 - Elagolix 2nd Phase 3 in Endometriosis
• 2H15 - Potential approval in US and EU for Humira in HS
• 2H15 - Completion of Humira phase 3 in uveitis and regulatory submissions
• 2H15 - Potential approval of HCV combo in Japan
• 2H15 - Majority of next-gen HCV (ABT-493/ABT-530) Phase 2b data and initiation of phase 3